Selected article for: "additional factor and liver dysfunction"
Author: Vitiello, Antonio; La Porta, Raffaele; D’Aiuto, Vilma; Ferrara, Francesco
Title: The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
  • Cord-id: oi7r4tf1
  • Document date: 2021_1_27
    • ID: oi7r4tf1
    Snippet: BACKGROUND: The global pandemic COVID-19 caused by the new coronavirus SARS-CoV-2 has already caused about 1.4 million deaths, and to date, there are no effective or direct antiviral vaccines. Some vaccines are in the last stages of testing. Overall mortality rates vary between countries, for example, from a minimum of 0.05% in Singapore to a maximum of 9.75 in Mexico; however, mortality and severity of COVID-19 are higher in the elderly and in those with comorbidities already present such as di
    Document: BACKGROUND: The global pandemic COVID-19 caused by the new coronavirus SARS-CoV-2 has already caused about 1.4 million deaths, and to date, there are no effective or direct antiviral vaccines. Some vaccines are in the last stages of testing. Overall mortality rates vary between countries, for example, from a minimum of 0.05% in Singapore to a maximum of 9.75 in Mexico; however, mortality and severity of COVID-19 are higher in the elderly and in those with comorbidities already present such as diabetes, hypertension, and heart disease. MAIN TEXT: Recent evidence has shown that an underlying liver disease can also be a risk factor, and SARS-CoV-2 itself can cause direct or indirect damage to liver tissue through multisystem inflammation generated especially in the more severe stages. In the current pandemic, liver dysfunction has been observed in 14–53% of patients with severe COVID-19. In addition, drugs administered during infection may be an additional factor of liver damage. The mechanism of cellular penetration of the virus that occurs by viral entry is through the receptors of the angiotensin 2 conversion enzyme (ACE-2) host that are abundantly present in type II pneumocytes, heart cells, but also liver cholangiocytes. CONCLUSION: In this manuscript, we describe the clinical management aimed at preserving the liver or reducing the damage caused by COVID-19 and anti-COVID-19 drug treatments.

    Search related documents:
    Co phrase search for related documents
    • abnormal liver and acute liver failure: 1, 2, 3, 4, 5, 6
    • abnormal liver and acute liver failure patient: 1
    • abnormal liver and acute liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • abnormal liver and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abnormal liver and liver aggravate: 1
    • abnormal liver and liver condition: 1, 2, 3
    • abnormal liver testing and acute respiratory syndrome: 1
    • acid derivative and acute liver injury: 1
    • acid derivative and acute respiratory syndrome: 1, 2
    • acid pathway and acute respiratory syndrome: 1, 2, 3, 4
    • acute hepatitis and administer therapy: 1
    • acute hepatitis and liver condition: 1
    • acute liver failure and administer therapy: 1
    • acute liver failure and liver condition: 1, 2, 3, 4, 5, 6, 7
    • acute liver injury and liver aggravate: 1, 2, 3
    • acute liver injury and liver condition: 1, 2
    • acute respiratory syndrome and administer therapy: 1, 2, 3
    • acute respiratory syndrome and liver aggravate: 1, 2
    • acute respiratory syndrome and liver condition: 1, 2